Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron
• Further strengthening of leadership team following the appointment of industry stalwart Barbara Angehrn Pavik as Chief Executive Officer
• Accelerating advancement of novel treatments to halt disease progression in neurodegenerative diseases
Lausanne, SWITZERLAND and San Francisco, CA, USA, 18 December 2023 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases with its exemplary pipeline of O-GlcNAcase (OGA) inhibitors, is pleased to announce the appointment of Abbas Hussain as new Chair to its Board of Directors.
